About Potassium channel subfamily T member 2
Potassium channel subfamily T member 2 (KCNT2) is a protein
from Homo sapiens identified by UniProt accession
Q6UVM3, 1135 residues long.
MolForge cross-references it against 0 known binders and
74 disease associations.
Target properties
| Protein name | Potassium channel subfamily T member 2 |
|---|
| UniProt accession | Q6UVM3 |
|---|
| Gene | KCNT2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1135 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (74)
Diseases linked to this target (Open Targets).
- developmental and epileptic encephalopathy · score 0.54
- Seizure · score 0.42
- epilepsy · score 0.37
- age-related macular degeneration · score 0.35
- complement factor H-related protein 5 measurement · score 0.29
- self reported educational attainment · score 0.27
- adolescent idiopathic scoliosis · score 0.24
- serum albumin measurement · score 0.23
- chronotype measurement · score 0.23
- complement factor H-related protein 1 measurement · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6UVM3-F1 | alphafold | PREDICTED | 76.12 | — |
Amino-acid sequence (1135 residues)
MVDLESEVPP LPPRYRFRDL LLGDQGWQND DRVQVEFYMN ENTFKERLKL FFIKNQRSSL RIRLFNFSLK LLSCLLYIIR VLLENPSQGN EWSHIFWVNR SLPLWGLQVS VALISLFETI LLGYLSYKGN IWEQILRIPF ILEIINAVPF IISIFWPSLR NLFVPVFLNC WLAKHALENM INDLHRAIQR TQSAMFNQVL ILISTLLCLI FTCICGIQHL ERIGKKLNLF DSLYFCIVTF STVGFGDVTP ETWSSKLFVV AMICVALVVL PIQFEQLAYL WMERQKSGGN YSRHRAQTEK HVVLCVSSLK IDLLMDFLNE FYAHPRLQDY YVVILCPTEM DVQVRRVLQI PMWSQRVIYL QGSALKDQDL LRAKMDDAEA CFILSSRCEV DRTSSDHQTI LRAWAVKDFA PNCPLYVQIL KPENKFHIKF ADHVVCEEEF KYAMLALNCI CPATSTLITL LVHTSRGQEG QQSPEQWQKM YGRCSGNEVY HIVLEESTFF AEYEGKSFTY ASFHAHKKFG VCLIGVRRED NKNILLNPGP RYIMNSTDIC FYINITKEEN SAFKNQDQQR KSNVSRSFYH GPSRLPVHSI IASMGTVAID LQDTSCRSAS GPTLSLPTEG SKEIRRPSIA PVLEVADTSS IQTCDLLSDQ SEDETTPDEE MSSNLEYAKG YPPYSPYIGS SPTFCHLLHE KVPFCCLRLD KSCQHNYYED AKAYGFKNKL IIVAAETAGN GLYNFIVPLR AYYRPKKELN PIVLLLDNPP DMHFLDAICW FPMVYYMVGS IDNLDDLLRC GVTFAANMVV VDKESTMSAE EDYMADAKTI VNVQTLFRLF SSLSIITELT HPANMRFMQF RAKDCYSLAL SKLEKKERER GSNLAFMFRL PFAAGRVFSI SMLDTLLYQS FVKDYMISIT RLLLGLDTTP GSGFLCSMKI TADDLWIRTY ARLYQKLCSS TGDVPIGIYR TESQKLTTSE SQISISVEEW EDTKDSKEQG HHRSNHRNST SSDQSDHPLL RRKSMQWARR LSRKGPKHSG KTAEKITQQR LNLYRRSERQ ELAELVKNRM KHLGLSTVGY DEMNDHQSTL SYILINPSPD TRIELNDVVY LIRPDPLAYL PNSEPSRRNS ICNVTGQDSR EETQL
Explore Potassium channel subfamily T member 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets